A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 562 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Mark Hoppus Of Blink-182 Announces He’s Cancer-Free October 8, 2021 New on NCI’s Websites for September 2023 September 29, 2023 Witness the Moment of Absolute Triumph as Baltimore Woman Is Finally... March 21, 2019 New ESMO Local and Locoregional Prostate Cancer Living Guideline v1.0 February 19, 2026 Load more HOT NEWS HPV Vaccine May Provide Men with “Herd Immunity” against Oral HPV... Touching a nerve: How neuroscience could advance our understanding of cancer 37-Year-Old Mom Breaks American Marathon Record Scientists find cells in centre of tumours are most likely to...
